EN
Abacus Medicine Group
Business Units

Management

The Abacus Medicine Group is headed by our Board of Directors and the Group Executive Team.

Board of Directors

Jens Albert
Chair of the Board

Jens Albert Harsaae

Read more
troels peter
Board Member

Troels Peter Troelsen

Read more
fleming wagner
CEO & majority shareholder

Flemming Wagner

Read more
anders bonding
Board Member

Anders K. Bønding

Read more
mark johnston
Board Member

Mark Johnston

Read more
img verbeek
Board Member

Alette Verbeek

Read more
img curran
Board Member

Sharon Curran

Read more

Group Executive Team

Flemming BW2
CEO & majority shareholder

Flemming Wagner

Lene BW
Chief Legal Officer (CLO)

Lene Bech McCormick

Frederik BW
Chief Commercial Officer (CCO)

Frederik Heupel

Peter Vd website edit
Chief Operating Officer (COO)

Peter van Duijvenbode

Niels website edit
Chief Finance Officer (CFO)

Niels Høy Nielsen

Sune BW
Chief Information Officer (CIO)

Sune Vorre

Eva BW
Chief People Officer (CPO)

Eva Berner

Kalman BW
Chief Executive Officer (CEO), Pluripharm

Kalman Petro

Jorg BW
Chief Commercial Officier (CCO), Abacus Medicine Pharmaceuticals

Jörg Schulze

Peter H website edit
Chief of Staff (CoS)

Peter Høj

Chairman of the Board

Jens Albert Harsaae

Mr. Harsaae joined the Board of Directors of Abacus Medicine in 2017.

Mr. Harsaae is a professional board member with a portfolio of positions as Chairman or member of non-executive/advisory boards in private equity or privately owned companies and start-ups. Previously, Mr. Harsaae was a Partner and the Managing Director for the Boston Consulting Group in Denmark, and Marketing Director for Procter & Gamble. Mr. Harsaae studied finance and marketing at the Aarhus School of Business and holds a master’s degree in economics.

Board Member

Troels Peter Troelsen

Mr. Troelsen is a Board Member. He served as Chairman of the Board of Directors from 2009 to 2020.

Mr. Troelsen is a highly experienced board member with more than 30 years of practice as chairman of several companies, extensive experience as CEO in large companies in both Denmark, UK and US, and 20 years of experience as associate professor at Copenhagen Business School with focus on pricing and sports economics. Mr. Troelsen holds a master’s degree in macroeconomics.

CEO & majority shareholder

Flemming Wagner

Mr. Wagner is CEO and majority shareholder of Abacus Medicine.

Prior to founding Abacus Medicine A/S in 2004, Mr. Wagner was the CEO of RAMCON A/S, a company focused on analytical and diagnostic equipment for hospitals and pharmaceutical industries. He holds an Executive MBA from Copenhagen Business School and a master’s degree in biochemistry from University of Copenhagen.

Board Member

Anders K. Bønding

Mr. Bønding joined the Board of Directors of Abacus Medicine in 2019.

Mr. Bønding is Founder and Partner at Greystone Capital Partners, and an experienced Chairman and Board member. As former Global Head of Corporate Finance with Danske Bank, he was responsible for origination, advisory and execution of over 100 equity capital markets and M&A transactions.

Mr. Bønding holds an MSc in Business & Finance from Copenhagen Business School (CBS).

Key Account Manager

Mark Johnston

Mr. Johnston joined the Board of Directors of Abacus Medicine in 2019.

Mr. Johnston is Managing Director at Chr. Augustinus Fabrikker Aktieselskab. Previously, Mr. Johnston was Director at Nordic Capital, and Investment Banker at Morgan Stanley.

Mr. Johnston studied finance at Copenhagen Business School and holds a master’s degree in Applied Economics and Finance.

Board Member

Alette Verbeek

Alette Verbeek joined the Board of Directors of Abacus Medicine in 2024.

Alette Verbeek is Senior Vice President of Global Strategic Partnering & Head of EU at Zai Lab.

Previously, Alette held leadership roles within Business Development and M&A at MSD and Novartis, where she drove commercial strategy in hospital and specialty care, as well as diversity and inclusion initiatives. She began her career as a pharmacist in the Netherlands.

Board Member

Sharon Curran

Sharon Curran joined the Board of Directors of Abacus Medicine in 2024.

Sharon Curran is an experienced non-executive board member at Norgine Ltd and Circassia Pharmaceuticals Plc.

Formerly, she was Vice President of Global Marketing at Abbvie, where she led franchises in neurosciences and niche/orphan diseases. Sharon has held roles at Novo Nordisk, Eli Lilly, and Abbott, bringing extensive expertise in strategy and market access.